Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

rifosine 50 mg daily or placebo. The Phase 3 trial design is based on positive data reported from the Phase 1/2 trial which was recently reported at the 51st American Society of Hematology meeting.

Patients eligible for the Phase 3 trial must have been previously treated with both bortezomib (Velcade(R)) and an immunomodulatory agent (Revlimid(R) and/or Thalidomid(R)), and been previously treated with one to four prior lines of therapy. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. Patients can be relapsed from and refractory to all non-bortezomib based therapies, however, patients can only be relapsed (progressed more than 60 days after discontinuing therapy) from prior bortezomib-based therapies. The study is powered at 90% to demonstrate the required difference in progression-free survival between the two arms. Approximately 265 events (defined as disease progression or death) will trigger the un-blinding of the data.

The Company expects a patient recruitment period of approximately 16-18 months, with study completion expected within approximately 20-22 months from today.

About Perifosine (KRX-0401)

Perifosine is a novel oral anticancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. Perifosine is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma for which it has received Orphan Drug and Fast Track designations from the FDA in this indication. Perifosine is also in Phase 2 clinical trials for several other tumor types.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but t
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation ... will be presenting at the Baird Healthcare Conference in ... and Chief Financial Officer, will be making a presentation ... EDT on Wednesday, Sept. 3, 2014. A ... the "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... , ... Board: LTUS) ("Lotus" or the "Company") a growing developer ... pharmaceutical,products in the People,s Republic of China ("PRC"), today ... operating entity of Lotus,appointed Mr. Jinzhong HAN to be ...
... ... a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited ... products for pregnant and nursing mothers. , ... Columbia, MD (Vocus) December 10, 2009 -- Martek Biosciences ...
... Collaboration to Create Optimized Antibodies Produces First Candidates Which ... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, ... program between YM and the National Research Council ... IntelliMab(TM) technology, the program is designed to generate novel ...
Cached Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/19/2014)... China,s increasing caesarean section rate, suggests a new commentary ... Journal of Obstetrics and Gynaecology (BJOG) . , China ... the world. Of 16 million babies born in 2010, ... is not known, the current Chinese language literature on ... from 36% to 58%. However, before the 1980s, the ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s not ... the Philippine tarsier: a tiny, adorable and downright "cool" primate ... that Americans are familiar with," said Rafe Brown, curator-in-charge at ... eyes and ears; an extremely cute, furry body; a long ... expanded fingers and toe tips that look a bit like ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... know Edward Teller as the "Father of the H-Bomb." To his ... detractors he was evil personified. Between these extremes was the life ... well researched attempt to interpret the enigmatic nature of a great ... beliefs," says G. A. Keyworth, II, science advisor to President Reagan, ...
... LAFAYETTE, Ind. - Greenhouse plant growers can substitute rice ... for an increase in growth regulators, according to a ... often consists of a soilless mix of peat and ... also regularly use plant-growth regulators to ensure consistent and ...
... Laxenburg, Austria 26th October 2010 --,A new assessment ... warming cautions that unless current imbalances in R&D portfolios ... technologies are redressed, greenhouse gas (GHG) emission reduction targets ... considerable costs. The study identifies energy efficiency as ...
Cached Biology News:'Judging Edward Teller' 2'Judging Edward Teller' 3Rice hulls a sustainable drainage option for greenhouse growers 2Changes in energy R&D needed to combat climate change 2Changes in energy R&D needed to combat climate change 3
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
LAL Chromogenic Endpoint assay...
...
Catch and Release® v2.0 Reversible Immunoprecipitation System...
Biology Products: